Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

(2021) Yair Herishanu et al.   BLOOD

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

(2021) Brian J. Boyarsky et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

(2021) Fulvia Pimpinelli et al.   Journal of Hematology & Oncology

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

(2021) Lindsey E. Roeker et al.   LEUKEMIA

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

(2021) William A. Werbel et al.   ANNALS OF INTERNAL MEDICINE

Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

(2021) Magdalena Benda et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Optimising SARS-CoV-2 vaccination schedules

(2021) Cristobal Belda-Iniesta   LANCET

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

(2021) Nassim Kamar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

(2021) Victoria G. Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

(2021) Florent Malard et al.   Blood Cancer Journal

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

(2021) David Hillus et al.   Lancet Respiratory Medicine

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

(2021) Amir Massarweh et al.   JAMA Oncology

COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis

(2021) Luigi Cavanna et al.   Vaccines

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

(2021) Rachna T. Shroff et al.   NATURE MEDICINE

COVID-19 in Immunocompromised Hosts: What We Know So Far

(2020) Monica Fung et al.   CLINICAL INFECTIOUS DISEASES

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

(2020) Abi Vijenthira et al.   BLOOD

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE